UK Prime Minister Keir Starmer praised the initiative, saying: “Unlocking opportunities for British businesses across the globe and delivering for working people back home is always the driving force behind my international engagements."
The Phase III programme, Enith1 and Enith2, is expected to launch this quarter
The early-stage trial demonstrated an excellent safety profile alongside clinically meaningful improvements in visual acuity
The EU approval of DAWNZERA is an important milestone that reflects our ongoing commitment to bring this innovative medicine to people in need across the globe
This innovation enhances viral stability, preserves potency, and reduces allergic reactions and antigen crystallisation-related issues
The Phase 1 single and multiple ascending dose study is set to begin dosing in early Q1 2026
The study evaluated patients with stage III/IV melanoma after complete tumor resection
Sofetabart mipitecan is a novel folate receptor alpha (FR?) antibody-drug conjugate (ADC) leveraging proprietary linker technology and an exatecan payload to target tumor cells
The expanded agreement significantly widens the scope of integrated services across the entire drug development lifecycle
Treatment typically requires frequent injections directly into the eye—an ongoing burden for patients and health systems alike
Subscribe To Our Newsletter & Stay Updated
